Clinical trials: Cognitive Dysfunction
Fall, Mild Cognitive Impairment (MCI)
Digital STEADI Efficacy
The aging of the U.S. population, combined with health care workforce shortages and insufficient access to effective fall prevention and exercise programs, has contributed to a high burden of fall-related injuries in older…
- Conditions
- Fall, Mild Cognitive Impairment (MCI), Aging
- Trial name
- NCT07852650
- Testing
- Digital STEADI-1, STEADI Standard of Care, Digital STEADI-2
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Friendi.fi Corporation
Alzheimer's Disease, Amnestic Mild Cognitive Impairment
Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment
This trial will determine the pharmacokinetics of Posiphen® in both plasma and CSF after a 10-day treatment period with Posiphen® in subjects with amnestic MCI.
- Trial name
- NCT01072812
- Testing
- Posiphen® tartrate capsules
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Annovis Bio Inc.
Cognitive Impairment
Ascending Dose Study of CT1812 in Healthy Volunteers
This is a double-blind, placebo controlled, ascending dose, multi-cohort trial. The study will be conducted in two phases: a single ascending dose (SAD) phase "Part A", followed by a multiple ascending dose (MAD) phase "Part B".
- Trial name
- NCT02570997
- Testing
- CT1812
- Where
- Australia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Cognition Therapeutics
Traumatic Brain Injury (TBI), Acquired Brain Injury
LearningRx Cognitive Training for Brain Injury
The purpose of this investigation is to conduct a series of case studies on the impact of LearningRx cognitive training on cognitive skills, daily functioning, and workplace self-efficacy for participants with Traumatic Brain…
- Conditions
- Traumatic Brain Injury (TBI), Acquired Brain Injury, Post COVID-19 Cognitive Impairment
- Trial name
- NCT02918994
- Testing
- LearningRx cognitive training
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Gibson Institute of Cognitive Research
Alzheimer's Disease, Mild Cognitive Impairment Due to Alzheimer's Disease
[18F]APN-1607 PET in Subjects With AD Compared to HC
The overall objective of this study is to compare the overall pattern of [18F]APN-1607 uptake in subjects with MCI, subjects with AD dementia, and healthy subjects.
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment Due to Alzheimer's Disease, Healthy Volunteers
- Trial name
- NCT05542953
- Testing
- [18F]APN-1607
- Where
- China
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- APRINOIA Therapeutics
Age-Related Cognitive Decline, Age-Related Memory Disorders
Memory Improvement With Docosahexaenoic Acid Study (MIDAS)
The purpose of this study is to investigate the effect of docosahexaenoic acid (DHA, 22:6n-3) in improving cognitive functions in subjects with age-related cognitive decline.
- Trial name
- MIDAS (NCT00278135)
- Where
- 14 sites in United States
- Volunteers
- 485 people
- Sponsor
- dsm-firmenich Switzerland AG
Age-related Functional Decline, Mild Cognitive Impairment
Health Benefits of Nutraceutical Supplementation in Older Adults.
This study examines a multi-ingredient nutraceutical designed to support several areas of health in older adults, including muscle strength, cognitive function, immune response, and inflammation.
- Trial name
- NCT07534878
- Testing
- Powder containing whey isolate and herbal extracts (30g sachet)
- Where
- India
- Volunteers
- 23 people
- Sponsor
- GPLIFE HEALTHCARE PRIVATE LIMITED
Ischemic Stroke Hospitalized, Impairment, Cognitive
A Study Testing How Well the Drug Extract of Ginkgo Biloba Leaves Tablets Works for People With Memory or Thinking Problems After a Stroke When Added to Standard Treatment
The goal of this clinical trial is to learn if Extract of Ginkgo Biloba Leaves Tablets help improve thinking and memory in people aged 55 years and older who had an ischemic stroke (a type of stroke caused by a blocked blood…
- Trial name
- GiCIIS (NCT07220538)
- Testing
- Extract of Ginkgo Biloba Leaves Tablets 240 mg (2 x 40 mg, t.i.d.), Standard of care (SoC) Group
- Where
- 40 sites in China
- Volunteers
- 400 people
- Sponsor
- Dr. Willmar Schwabe GmbH & Co. KG
Alzheimer's Disease (AD), Mild Cognitive Impairment (MCI)
Evaluation of SCALE PET Software for Quantitative Brain PET Analysis in Alzheimer's Disease
The goal of this study is to learn if medical image analysis software, Neurophet SCALE PET, can enhance readers' amyloid beta positivity performance in people with Alzheimer's Disease.
- Trial name
- NCT07417540
- Testing
- Neurophet SCALE PET
- Where
- South Korea
- Volunteers
- 190 people
- Sponsor
- NEUROPHET
Schizophrenia
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
This is an efficacy study evaluating a experimental treatment for cognitive deficits in adults with schizophrenia.
- Trial name
- NCT01678755
- Testing
- ABT-126
- Where
- 20 sites in United States
- Volunteers
- 157 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Dementia, Alzheimer Disease 1
Study of APH-1105 in Patients With Mild to Moderate Alzheimer's Disease
This is a Phase 2 study assessing the safety, tolerability and efficacy of intranasal delivery of APH-1105 for the treatment of mild to moderate Alzheimer's in adult.
- Conditions
- Dementia, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3
- Trial name
- NCT03806478
- Testing
- APH-1105
- Volunteers
- 60 people
- Sponsor
- Aphios
Alzheimer's Disease
Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects
A Phase 2/3 cross-sectional and longitudinal observational study evaluating imaging characteristics of flortaucipir in control subjects and patients with clinically defined MCI and AD dementia (AD).
- Trial name
- MCI (NCT02016560)
- Testing
- florbetapir F 18, Flortaucipir F18, Brain PET Scan
- Where
- 27 sites in United States
- Volunteers
- 383 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer's Disease, Amnestic Mild Cognitive Impairment
Brain Uptake and Safety With Probable Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Healthy Volunteers
Study to Assess Brain Uptake and Safety of AH110690 (18F) Injection in Subjects with Probable Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Healthy Volunteers.
- Trial name
- ALZ201 (NCT00785759)
- Testing
- AH110690 (18F) Injection
- Where
- Norway
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease Dementia
A Study of Clenbuterol (CST-103) Co-administered With Nadolol (CST-107) in Subjects With Neurodegenerative Disorders
This is a Phase II, randomized, placebo-controlled, double-blind, crossover study on the CNS and pharmacodynamic effects of clenbuterol (CST-103) co-administered with nadolol (CST-107) in 4 subject populations with…
- Trial name
- CLIN-011 (NCT04739423)
- Where
- 7 sites in Australia, New Zealand and 1 more
- Volunteers
- 41 people
- Sponsor
- CuraSen Therapeutics, Inc.
Mild Cognitive Impairment, Ischemic Stroke
Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Early Recovery Stage After Ischemic Stroke
The purpose of this study is: to evaluate efficacy of MMH-MAP in the treatment of mild cognitive impairment in subjects in early rehabilitation period of ischemic stroke to evaluate safety of MMH-MAP in the treatment of mild…
- Trial name
- NCT03815292
- Testing
- MMH-MAP
- Where
- 28 sites in Russia
- Volunteers
- 276 people
- Sponsor
- Materia Medica Holding
Cognitive Disorder
A Study to Investigate the Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-D4010 in Healthy Subjects
The purpose of the study is to evaluate the effect of food, gender, and age on the single-dose pharmacokinetics (PK) of SUVN-D4010.
- Trial name
- NCT03031574
- Testing
- SUVN-D4010
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Suven Life Sciences Limited
Alzheimer Disease
A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01
This is a Phase Ia/Ib, two-part, randomized, placebo-controlled, double-blinded, first in human(FIH) study to evaluate the safety, tolerability, PK, and PD of ADEL-Y01 in healthy participants in Part 1 and participants with MCI…
- Trial name
- NCT06247345
- Testing
- ADEL-Y01 - healty participants, ADEL-Y01 - MCI/AD
- Where
- 6 sites in United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Alzheimer's Disease Expert Lab (ADEL), Inc.
Alzheimer's Disease
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
The purpose of this Phase 1/Phase 2 study is to evaluate how the body handles the drug and the drug's effect on the body of participants with mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) or mild AD and who test…
- Trial name
- NCT01561430
- Testing
- LY2886721
- Where
- 34 sites in United States, Italy and 3 more
- Volunteers
- 70 people
- Sponsor
- Eli Lilly and Company
Mild Cognitive Impairment, Mild Dementia
A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)
The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance in participants with Alzheimer's Disease.
- Conditions
- Mild Cognitive Impairment, Mild Dementia, Alzheimer's Disease
- Trial name
- NCT05619692
- Testing
- SAGE-718
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 174 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Migraine Headache, Cognitive Impairment
Treximet in Acute Migraine Headache: Assessing Cognitive Function
Migraine headache occurs frequently in women more than men and is associated with symptoms not only of significant pain but also of symptoms typically including of photophobia, phonophobia, nausea and vomiting.
- Trial name
- NCT00837044
- Testing
- Treximet, Migraine rescue medication of choice
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Neurological Research Center